Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy

Abstract

Public reporting burden for this collection of information Is estimated to average 1 hour per response, Including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, ABSTRACT (Maximum 200 Words)Gene therapy holds great promise for treatment of breast cancer. In particular, clinical trials are underway to apply therapeutic genes related to pro-drug activation or to modulate the activity of oncogenes by blocking promoter sites. However, there are major problems in terms of assessing the delivery to target tissue, assessing the uniformity (versus heterogeneity) of biodistribution and determining whether the genes are expressed. We propose to design, evaluate and apply a novel approach to gene activity detection-specifically, using fluorinated substrates of P-galactosidase to reveal gene activity. Our prototype molecule PFONPG (para-fluoro-ortho-nitro-phenyl P3-D-galactopyranoside) is a direct analog of the traditional "yellow' biochemical indicator ONPG (ortho-nitro-phenyl 3-D-galactopyranoside). This shows useful MR characteristics, sensitivity to enzyme activity and ability to enter cells. We will synthesize analogs of this prototype to optimize MR and biological characteristics and explore the feasibility of tailoring the reporter to specific applications, e.g., exploiting P-gal activity to deliver specific physiological reporter molecules such as pH and potentially specific cytotoxic agents. The agents will be rigorously tested in solution, applied to cultured breast cancer cells and ultimately used to examine P-gal activity in vivo in transfected breast tumors in mice and rats. SUBJECT TERMS NUMBER OF PAGESGene therapy, fluorine NMR, P-galactosidase, pH 127 IntroductionGene therapy holds great promise for treatment of breast cancer (1, 2). In particular, clinical trials are underway to apply therapeutic genes related to pro-drug activation or modulation of the activity of oncogenes by blocking promoter sites. However, there are major problems in terms of assessing the delivery to target tissue, assessing the uniformity (versus heterogeneity) of biodistribution and determining whether the genes are expressed. We propose to design, evaluate and apply a novel approach to gene activity detection-specifically, using fluorinated substrates of P3-galactosidase to reveal gene activity. Our prototype molecule PFONPG (para-fluoro-ortho-nitro-phenyl [3-D-galactopyranoside) is a direct analog of the traditional "yellow' biochemical indicator ONPG (ortho-nitro-phenyl 13-D-galactopyranoside).This shows useful MR characteristics, sensitivity to enzyme activity ...